Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003135
Status:
UNKNOWN
Last Update Posted:
2009-04-30
First Post:
1999-11-01
Brief Title:
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast Ovarian Endometrial or Cervical Cancer
Sponsor:
The University of Texas Health Science Center Houston
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin5-Fluorouracil in Patients With Advanced Malignancy
Status:
UNKNOWN
Status Verified Date:
2008-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining chemotherapy with hyperthermia may kill more tumor cells
PURPOSE This phase II trial is studying how well giving fluorouracil and liposomal doxorubicin together with systemic hyperthermia works in treating patients with metastatic breast ovarian endometrial or cervical cancer
PURPOSE This phase II trial is studying how well giving fluorouracil and liposomal doxorubicin together with systemic hyperthermia works in treating patients with metastatic breast ovarian endometrial or cervical cancer
Detailed Description:
OBJECTIVES
Evaluate tumor response and toxicity induced by fluorouracil and doxorubicin HCl liposome combined with mild systemic hyperthermia in patients with metastatic breast ovarian endometrial or cervical cancer
OUTLINE This is a time-escalation study of systemic hyperthermia
Patients receive fluorouracil IV continuously over 24 hours on days 1-5 and doxorubicin HCl liposome IV over 30 minutes on day 6 Beginning on day 7 patients receive heat applied for 6-24 hours in 6-hour sequential treatments using a mild hyperthermia-induction device Treatment repeats every 4-5 weeks for a total of 4 courses Patients who achieve less than a complete response but have no disease progression may receive additional courses of chemotherapy alone
Cohorts of 5 patients receive escalating durations of hyperthermia until the recommended phase II duration is determined The recommended phase II duration of hyperthermia is defined as the level preceding that at which 1 of 5 patients experiences measurable toxicity Phase I closed as of 92801
Patients are followed at 4 weeks and then every 6 months for 1 year
PROJECTED ACCRUAL A maximum of 34 patients will be accrued for this study within 48 months
Evaluate tumor response and toxicity induced by fluorouracil and doxorubicin HCl liposome combined with mild systemic hyperthermia in patients with metastatic breast ovarian endometrial or cervical cancer
OUTLINE This is a time-escalation study of systemic hyperthermia
Patients receive fluorouracil IV continuously over 24 hours on days 1-5 and doxorubicin HCl liposome IV over 30 minutes on day 6 Beginning on day 7 patients receive heat applied for 6-24 hours in 6-hour sequential treatments using a mild hyperthermia-induction device Treatment repeats every 4-5 weeks for a total of 4 courses Patients who achieve less than a complete response but have no disease progression may receive additional courses of chemotherapy alone
Cohorts of 5 patients receive escalating durations of hyperthermia until the recommended phase II duration is determined The recommended phase II duration of hyperthermia is defined as the level preceding that at which 1 of 5 patients experiences measurable toxicity Phase I closed as of 92801
Patients are followed at 4 weeks and then every 6 months for 1 year
PROJECTED ACCRUAL A maximum of 34 patients will be accrued for this study within 48 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-V97-1356 | None | None | None |
| UTHSC-MS-96205 | None | None | None |